The side effects of drugs used for the treatment of lupus is expected to hinder the growth of the global lupus therapeutic market over the forecast period. For instance, according to an article published by the Lupus Science and Medicine Journal (a peer-reviewed, open access journal) in March 2020, nearly all patients undergoing treatment for SLE report one or more adverse events such as nausea, vomiting, bone toxicity, and others.
Market Opportunities: Increasing Research and Development Activities
Increasing research and development activities among key market players is expected to offer lucrative growth opportunities over the forecast period. For instance, in November 2021, AstraZeneca, a U.K.-based biopharmaceutical company, announced positive results from its TULIP Phase 3 clinical trial program (focused on determining the efficacy and safety of Anifrolumab), stating that Saphnelo (anifrolumab) - a human monoclonal antibody showed greater reduction of SLE when used in combination with standard therapy than the use of only standard therapy.
Lupus Therapeutic Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients